Whether it is to purify, cleanse, accelerate healing or close the wound, the LINK Medical Technologies range from URGO has a product to suit.
The next generation for chronic and reoccurring wounds is URGOSTART.® Incorporating Lipido-Colloid Technology (LCT), along with its unique accelerating compound NOSF to rebalance wound equilibrium and neutralise proteases, URGOSTART® has been clinically shown to promote faster healing therefore saving nursing time and to improve patient's quality of life with less pain and less trauma.
LINK Medical Technologies and Urgo Medical in partnership are committed to supporting families affected by Epidermolysis-Bullosa (EB). More information on EB can be found on: www.epidermolysis-bullosa.com
LINK Healthcare is a privately owned Australian-based specialist Pharmaceutical and Medical Technology business. LINK's mission is to strive for excellence in the marketing of a vitally important and unique range of specialist products that enhance the well-being of thousands of people in the region.
LINK provides exceptional sales and marketing infrastructure and is partnered with blue chip pharmaceutical companies from around the world, allowing the company to offer a unique and substantial portfolio of'medicine that matters.'
At LINK Healthcare we focus on specialist pharmaceutical products and medical devices. Our pharmaceutical range consists of both proprietary and in-licensed products. While seeking the development and acquisition of our own products, we are also committed to building lasting ongoing relationships with partner companies around the world. Our substantial infrastructure and breadth of experience means that partner products become firmly embedded within our existing range as well as in the markets in which we operate.
Our partners are a wide variety of pharmaceutical businesses which are interested in streamlining their distribution and marketing, or expanding their business with a single organisation covering our entire region of Australia, New Zealand, South Africa or South East Asia.